Market revenue in 2023 | USD 6.2 million |
Market revenue in 2030 | USD 8.0 million |
Growth rate | 3.7% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 62.9% in 2023. Horizon Databook has segmented the UAE pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Several favorable strategic initiatives have been undertaken in the country. In April 2022, Viafet Genomics Laboratory collaborated with Euformatics to provide carrier screening and clinical diagnostics in the UAE. Similarly, in July 2022, G42 Healthcare expanded its clinical genetics offerings with the launch of 250 comprehensive testing panels with the shortest turnaround time.
Moreover, the UAE is one of the leading contributors to the cancer burden in the MEA. According to UAE National Cancer Registry in 2019, the country reported over 4,633 new cancer cases, of which 4,381 were malignant and 252 were in situ cases.
Hence, the high disease burden in the country is expected to fuel the demand for new cancer testing laboratories with advanced diagnostics tests. In May 2020, a new liquid biopsy laboratory was established at the Thumbay Research Institute for Precision Medicine at the Gulf Medical University. This laboratory facilitated cancer diagnosis and management in the UAE.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into UAE pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account